Inhaled Epinephrine
Phase 1Small molecule
Inhaled Epinephrine is one of 29 small molecule programs targeting Allergy. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
149 competitors in Allergy
#DrugCompanyPhaseTrials
1Flovent
GSKPhase 3
Clarinex
OOrganon and Co
Phase 3
REGN5715
RegeneronPhase 3
REGN5713
RegeneronPhase 3
Rhapsido
NovartisPhase 2
Ligelizumab
NovartisPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 2
DUPIXENT
RegeneronPhase 2
Allergy Immunotherapy (AIT)
AALK-Abelló A/S
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Allergy2 trials
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges
Completed·—·Phase 1·NCT06445374·21 enrolled
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges
Recruiting·—·Phase 1·NCT07038746·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled Epinephrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDr. George Luciuk